NSE - Delayed Quote INR

Krebs Biochemicals & Industries Limited (KREBSBIO.NS)

87.81
-2.20
(-2.44%)
At close: June 13 at 3:29:39 PM GMT+5:30
Loading Chart for KREBSBIO.NS
  • Previous Close 90.01
  • Open 88.00
  • Bid --
  • Ask --
  • Day's Range 86.34 - 89.90
  • 52 Week Range 66.12 - 129.07
  • Volume 13,058
  • Avg. Volume 24,483
  • Market Cap (intraday) 1.901B
  • Beta (5Y Monthly) 0.62
  • PE Ratio (TTM) --
  • EPS (TTM) -12.49
  • Earnings Date Aug 5, 2025 - Aug 9, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date Sep 14, 2005
  • 1y Target Est --

Krebs Biochemicals & Industries Limited engages in the manufacture and sale of active pharmaceutical ingredients in India. The company develops biotech processes for application in medicine, agriculture, and industry. Its products include androstenedione, lovastatin, and simvastatin, which are used for anti-cholesterol and steroid intermediate applications. The company also develops various products, including amlodipine, cetirizine, orlistat, serratiopepetidase, telmisartan, and phenylephrine for anti-hypertension, anti-histamine, anti-obesity, anti-inflammatory, and cold and cough applications. In addition, it offers contract manufacturing services for large pharmaceutical and multinational companies. The company was incorporated in 1991 and is based in Visakhapatnam, India.

krebsbiochem.com

--

Full Time Employees

March 31

Fiscal Year Ends

Recent News: KREBSBIO.NS

View More

Performance Overview: KREBSBIO.NS

Trailing total returns as of 6/13/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .

YTD Return

KREBSBIO.NS
5.57%
S&P BSE SENSEX (^BSESN)
3.81%

1-Year Return

KREBSBIO.NS
20.72%
S&P BSE SENSEX (^BSESN)
5.61%

3-Year Return

KREBSBIO.NS
20.46%
S&P BSE SENSEX (^BSESN)
53.50%

5-Year Return

KREBSBIO.NS
5.73%
S&P BSE SENSEX (^BSESN)
140.13%

Compare To: KREBSBIO.NS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: KREBSBIO.NS

View More

Valuation Measures

Annual
As of 6/13/2025
  • Market Cap

    1.90B

  • Enterprise Value

    4.02B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    4.37

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    9.28

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -62.20%

  • Return on Assets (ttm)

    -7.56%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    433.12M

  • Net Income Avi to Common (ttm)

    -269.39M

  • Diluted EPS (ttm)

    -12.49

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.42M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -56.05M

Research Analysis: KREBSBIO.NS

View More

Company Insights: KREBSBIO.NS

Research Reports: KREBSBIO.NS

View More

People Also Watch